Profound neutropenia related to consolidation durvalumab treatment following concurrent radiochemotherapy in a patient with stage III non-small‑cell lung cancer

Pol Arch Intern Med. 2022 Feb 28;132(2):16161. doi: 10.20452/pamw.16161. Epub 2021 Dec 1.

Authors

Artur Bandura¹, Michał Kurlapski², Małgorzata Kamińska³, Rafał Dziadziuszko^{3

4}, Jacek Jassem⁴

Affiliations

¹ Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdańsk, Poland. abandura@gumed.edu.pl
² Department of Hematology, Medical University of Gdansk, Gdańsk, Poland
³ Early Clinical Trials Center, Medical University of Gdansk, Gdańsk, Poland
⁴ Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdańsk, Poland

PMID: 34851079
DOI: 10.20452/pamw.16161

No abstract available

MeSH terms

Antibodies, Monoclonal* / adverse effects
Carcinoma, Non-Small-Cell Lung* / pathology
Carcinoma, Non-Small-Cell Lung* / therapy
Chemoradiotherapy
Humans
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
Neoplasm Staging
Neutropenia* / etiology

Substances

Antibodies, Monoclonal
durvalumab